MedTrace Logo

Hemophilia Mobile App Usability Pilot

NCT03168685 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-04-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the utility and user experience of a smart phone app for people with medical conditions, used in conjunction with an ActiGraph wearable device and a connected scale.

Conditions

Interventions

DEVICE

SureSource Engage application

Eligible patients who choose to participate in the study will be asked to wear an actigraphy device \[ActiGraph GT9X Link "Actigraph Link"\] on their wrist continuously during both 4-week study phases. The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position. The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices. Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Healthcare Innovation Technology Lab

    lead INDUSTRY

Principal Investigators

  • Stan Kachnowski, PhD, MPA · Healthcare Innovation Technology Lab

  • Ryan Dammerman, MD · Healthcare Innovation Technology Lab

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
63 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-22
Primary Completion
2018-05-11
Completion
2018-05-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03168685 on ClinicalTrials.gov